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Liver biopsy is still considered the gold standard for
staging fibrosis in chronic liver diseases. However, liver
biopsy is an invasive procedure, and complications occur in
0.6%-5% of patients [1,2]. In addition, to perform the procedure
there is a need for additional resources such as
ultrasonography. Therefore, as a rule, patients undergoing
liver biopsy are hospitalized for at least 6 hours [3].
Recent studies involving patients with chronic hepatitis
C showed that fragments of technically inadequate hepatic
tissue frequently lead to the underestimation of the stage of
liver fibrosis [4]. That rate of diagnostic error can vary from
10%-30% depending on the study [5]. In addition, in developed
countries, there is greater patient resistance to undergoing
biopsy.
In Brazil, there is an additional factor, which is that patients
are obligated to submit to liver biopsy for indication of
treatment, except in clinically confirmed cases of hepatic
cirrhosis according to the Ministry of Health guidelines.
For all of these reasons, an increasing number of studies
are being conducted in order to evaluate the effectiveness of
noninvasive markers for staging liver fibrosis. The
noninvasive methods used in the largest number of published
studies are the calculation of two indices - the aspartate
aminotransferase (AST) to platelet ratio index (APRI) and the
FibroTest index - and the FibroScan test.
The effectiveness of the various methods evaluated in
various studies revealed quite heterogeneous results. The
APRI method and the Forns index are unable to stage a large
percentage of patients, and their accuracies do not exceed
80%-85%. Therefore, a considerable number of patients are
required to undergo liver biopsy. Otherwise, approximately
20% would be incorrectly diagnosed. The efficacy of those
methods encounters difficulty regarding standardization and
the definition of cut-off values for each degree of fibrosis.
APRI
The APRI was developed by Wai et al. [6] and is calculated
based on AST levels and platelet counts. According to the
results obtained in that study, the lower and upper cut-off
values for the definition of significant fibrosis and cirrhosis
are determined. Through analysis of the results, the positive
and negative predictive values for the presence or absence of
significant fibrosis or cirrhosis are also determined.
To evaluate significant fibrosis, the following cut-off
values are used: lower than 0.5 (absence of significant fibrosis,
Ishak stage 0-2); and higher than 1.5 (presence of significant
fibrosis, Ishak stage 3-6) [6]. To evaluate cirrhosis, different
cut-off values are used. The absence of cirrhosis (Ishak stage
0-4) is defined as values lower than 1, and cirrhosis (Ishak
stage 5-6) is defined as values higher than 2 [6]. The formula
for calculating the APRI test is as follows:
APRI = AST(/LSN) × 100 / Platelets (109/L)
Table 1 shows the APRI values obtained.
* This article is part of the Proceedings of the Consensus of the Brazilian Society of Infectious Diseases on the Management and Treatment of
Hepatitis C presented in the supplement of the Brazilian Journal of Infectious Diseases.
Table 1. The aspartate aminotransferase to platelet ratio index
results obtained by Wai et al.
Therefore, the aforementioned Wai et al. showed that the
APRI has a high positive predictive value to identify patients
with significant fibrosis and a high negative predictive value
to rule out cirrhosis. That study also showed that it is possible
to predict the presence or absence of significant fibrosis in
51% of patients and to predict the presence or absence of
cirrhosis in 81% of patients [6].
FibroTest
FibroTest combines and analyzes the serum levels of five
factors in patients with chronic hepatitis C. Those five factors
are bilirubin, gamma-glutamyl transferase, apolipoprotein A1,
alpha-2-macroglobulin and haptoglobin. The results obtained
are evaluated through a formula which predicts and classifies
them as F0-1, F2-3 and F4 [7].
FibroScan - A New Noninvasive Method
The evaluation of the degree of liver fibrosis is of
fundamental importance to the prognosis, follow-up and
therapeutic decision-making for patients with chronic liver
disease. Biopsy is an invasive method and occasionally
(although rarely) results in complications. In addition, the
biopsy results, from an anatomical-pathological point of view,
are often evaluated subjectively [8,9]. Nevertheless, biopsy
continues to be the gold standard by which fibrosis is staged
and evaluated
There are various studies on noninvasive options in the
staging, evaluation and monitoring of liver fibrosis. FibroScan
Cut-Off PPV NPV
No Fibrosis < 0.5 64% 90%
Fibrosis > 1.5 91% 65%
No Cirrhosis < 1.0 35% 100%
Cirrhosis > 2.0 65% 95%
PPV=positive predictive value; NPV=negative predictive value.
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Figure 1. Algorithm proposed by Sebastiani et al. (EASL) [14], in which the aspartate aminotransferase to platelet ratio index
(APRI) method is used in conjunction with FibroTest.
ALT=alanine aminotransferase; UDE=upper digestive tract endoscopy; US=ultrasound.
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Figure 2. Algorithm proposed by Castéra et al. [15], in which the FibroTest results are evaluated together with the FibroScan
results.
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is a new method, still only available on a small scale, which
presents better results in various studies with respect to
differentiating between cirrhotic and noncirrhotic patients. It
is considered a quick and easy noninvasive procedure for
diagnosing cirrhosis and has been presented as an alternative
to liver biopsy in patients with a formal contraindication [8].
FibroScan measures hepatic elasticity through a transducer
positioned intercostally on the skin over the right lobe of the
liver. The transducer transmits low amplitude and low
frequency vibration pulses to the hepatic tissue. This
vibration pulses propagate an elastic wave whose velocity is
directly related to the elasticity of the tissue. Results are given
in kilopascals (kPa).
Some studies have shown that body mass index and
age of the patient, as well as the level of experience on the
part of the health professional, can influence the FibroScan
results of patients with chronic hepatitis C. The body mass
index and steatosis can affect the evaluation of fibrosis,
although some studies have shown that those factors are
minimized if the test is repeated a fair number of times.
Some studies recommend a total of five measurements to
validate the results [10].
For the detection of fibrosis ≥ F2, FibroScan presents
85.2% sensitivity, 90.7% specificity, 93.8% positive predictive
value, 78.8% negative predictive value and 87.7% diagnostic
power. For the detection of cirrhosis, the test presents 78.3%
sensitivity, 98.2% specificity, 97.8% positive predictive value,
81.6% negative predictive value and 88.2% diagnostic power
[11-13].
Despite the reasonable quantity of published studies, few
have compared the methods in a randomized manner. There
are two studies that propose algorithms for evaluation. The
first study, published by the European Association for the
Study of the Liver (EASL), aims to standardize and compare
the various methods based on serum markers of liver fibrosis.
In its conclusion, the study proposes the use of an organogram
that could reduce the need for liver biopsy by 60%-70% [14].
That study, conducted by Sebastiani et al. [14],
evaluated the capacity of different methods to diagnose
significant fibrosis (METAVIR fibrosis score ≥ 2) in patients
with normal or high levels of transaminase and to diagnose
cirrhosis (Figure 1).
The results obtained show that significant fibrosis can be
diagnosed with an accuracy of 94% using the APRI as the
first screening test, followed by FibroTest in patients who
were not classified through the APRI method, thereby limiting
biopsy to only those patients in whom the degree of fibrosis
is classified as F0-F1 using noninvasive methods [14].
Cirrhosis can also be diagnosed through this algorithm
(95% accuracy). The authors considered that in their original
study they might have obtained highly favorable results due
to the fact that the majority of patients presented significant
fibrosis. The principal limitation of these markers is the
difficulty in obtaining confirmation for patients with F0-F1
fibrosis. Therefore, an algorithm for the evaluation of fibrosis
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Table 2. FibroScan results
that attempts to define which patients are not required to
undergo liver biopsy was developed.
Another study conducted by Castéra et al. [15] compared
the effectiveness of transitory hepatic elastography
(FibroScan, Echosens, Paris, France) in relation to the APRI
and FibroTest. It succeeded in showing that FibroScan has a
great capacity to diagnose significant fibrosis (≥ F2) (Figure
2). The results can be seen in Table 2.
Therefore, it can be seen that FibroScan presents a high
positive predictive value for patients with fibrosis ≥ F2 and an
excellent negative predictive value for patients with hepatic
cirrhosis. It is undoubtedly a good method for demonstrating
significant fibrosis or for ruling out hepatic cirrhosis.
The study conducted by Castéra et al. proposes the
combination of FibroScan and FibroTest as a screening method
for significant fibrosis. When there was concordance between
the methods, which occurred in 70%-80% of patients, the
compatibility with the liver biopsy was 84% in diagnosing
fibrosis ≥ F2, 95% in diagnosing fibrosis ≥ F3, and a 94% in
diagnosing cirrhosis (F4).
Therefore, much still needs to be studied in relation to the
noninvasive methods for estimating the degree of fibrosis,
which is why it is necessary to carry out randomized
comparative studies involving different patient populations.
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